Dr. Traina on the Effects of Elacestrant in ER+, HER2- Breast Cancer

Tiffany A. Traina, MD, medical oncologist, vice chair, Oncology Care, Department of Medicine, section head, Triple Negative Breast Cancer Clinical Research Program, Memorial Sloan Kettering Cancer Center, discusses the implications of the phase 3 EMERALD trial (NCT03778931) in advanced estrogen receptor (ER)–positive, HER2-negative breast cancer.

EMERALD compared standard-of-care endocrine therapy with elacestrant, which is now the first oral selective ER degrader (SERD) to demonstrate efficacy in patients with ER-positive, HER2-negative disease who previously received CDK4/6 inhibition in a phase 3 trial, Traina says.Data presented at the 2021 San Antonio Breast Cancer Symposium by Aditya Bardia, MD, MPH, of Massachusetts General Hospital, showed the SERD achieved a median progression-free survival of 2.79 months vs 1.91 months with standard endocrine therapy in the intent-to-treat population (HR, 0.697; 95% CI, 0.552-0.880; P = .0018).

Along with a manageable safety profile, elacestrant elicited responses in patients who had prior exposure to fulvestrant (Faslodex), Traina continues. Elacestrant could expand options for this patient population as an additional line of endocrine therapy, Traina concludes.